Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

DiPLA

From Wikipedia, the free encyclopedia
(Redirected fromDiisopropyllysergamide)

Pharmaceutical compound
DiPLA
Clinical data
Other namesDiPLA;N,N-Diisopropyllysergamide; Lysergic acid diisopropylamide
Drug classSerotonin receptor modulator;Serotonergic psychedelic;Hallucinogen
ATC code
  • None
Identifiers
  • (6aR,9R)-7-methyl-N,N-di(propan-2-yl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
PubChemCID
Chemical and physical data
FormulaC22H29N3O
Molar mass351.494 g·mol−1
3D model (JSmol)
  • CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(C)C)C(C)C
  • InChI=1S/C22H29N3O/c1-13(2)25(14(3)4)22(26)16-9-18-17-7-6-8-19-21(17)15(11-23-19)10-20(18)24(5)12-16/h6-9,11,13-14,16,20,23H,10,12H2,1-5H3/t16-,20-/m1/s1
  • Key:UGLFFFFNSMDCNO-OXQOHEQNSA-N

DiPLA, also known asN,N-diisopropyllysergamide or aslysergic acid diisopropylamide, is a putativeserotonergic psychedelic of thelysergamide family related tolysergic acid diethylamide (LSD).[1][2][3][4] It is theanalogue of LSD in which theN,N-diethyl groups have been replaced withN,N-diisopropyl groups.[3][2][5]

Use and effects

[edit]

DiPLA is not known to have been assessed in humans.[3][6]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

In an early study, DiPLA showed 23.2% of theantiserotonergic activity of LSD in the isolated ratuterus and hence was about 4-fold lesspotent than LSD in thisassay.[3][4][7] Subsequently, DIPLA was reported to have anaffinity (Ki) for theserotonin5-HT2A receptor of 9.0 to 20.2 nM, which was about 4- to 9-fold lower than that of LSD (Ki = 4.8 nM).[8][2][5][9] It is anagonist of the serotonin 5-HT2A receptor and also interacts with other receptors such as the serotonin5-HT1A receptor, the serotonin5-HT2C receptor, anddopamine receptors.[8][1] DIPLA fully substituted for LSD in rodentdrug discrimination tests, suggesting that it could havepsychedelic effects in humans.[2][9] Unlike other assessed lysergamides however, DIPLA was much less potent than LSD, about 8-fold so in the drug discrimination test.[5][9]

History

[edit]

DiPLA was first described in thescientific literature byAlbert Hofmann and colleagues by 1955.[10][11] Subsequently, it was studied in more detail byDavid E. Nichols and colleagues in the 1990s and thereafter.[2][5][9][1]

See also

[edit]

References

[edit]
  1. ^abcJain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, et al. (July 2025)."The polypharmacology of psychedelics reveals multiple targets for potential therapeutics"(PDF).Neuron.113 (19): 3129–3142.e9.doi:10.1016/j.neuron.2025.06.012.PMID 40683247.
  2. ^abcdePfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994)."Lysergamides revisited"(PDF).NIDA Research Monograph.146:52–73.PMID 8742794.The series of isopropyl amides has recently been completed with the synthesis of the N-isopropyl, in addition to the N-methyl-N-isopropyl, N-ethyl-N-isopropyl, and the N,N-diisopropyl, as shown in figure 12. With the exception of the N,N-diisopropylamide, all compounds completely substitute in the DD paradigm in rats trained to discriminate LSD from saline. In table 6, the receptor-binding data for displacement of [ 3H]-ketanserin from rat cortical homogenate are shown. Although all N-isopropyl homologs have only 25 to 30 percent affinity of LSD for this site, it is interesting to note that the N-methyl-N-isopropyl compound discussed earlier has nearly equal affinity to LSD for the 5-HT2 site labeled with the agonist ligand [ 125I]-R-DOI. This illustrates the importance of determining the relative efficacy of these compounds rather than just receptor affinity. [...] TABLE 6. Radioligand binding data for N-methyl-N-isopropyl lysergamides: [ 3H]-ketanserin displacement (unpublished results).
  3. ^abcdOberlender RA (May 1989)."Stereoselective aspects of hallucinogenic drug action and drug discrimination studies of entactogens".Purdue e-Pubs. Purdue University.Table 2. Relative potency values for lysergic acid amides. [...]
  4. ^abCerletti A, Doepfner W (January 1958)."Comparative study on the serotonin antagonism of amide derivatives of lysergic acid and of ergot alkaloids".The Journal of Pharmacology and Experimental Therapeutics.122 (1):124–136.doi:10.1016/S0022-3565(25)11933-2.PMID 13502837. Archived fromthe original on 2025-06-30.
  5. ^abcdHuang X, Marona-Lewicka D, Pfaff RC, Nichols DE (1994)."Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives".Pharmacology Biochemistry and Behavior.47 (3):667–673.doi:10.1016/0091-3057(94)90172-4.PMID 8208787. Retrieved27 July 2025.
  6. ^Shulgin AT (2003)."Basic Pharmacology and Effects". In Laing RR (ed.).Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137.ISBN 978-0-12-433951-4.
  7. ^Rothlin E (March 1957)."Lysergic acid diethylamide and related substances".Annals of the New York Academy of Sciences.66 (3):668–676.Bibcode:1957NYASA..66..668R.doi:10.1111/j.1749-6632.1957.tb40756.x.PMID 13425249. Archived fromthe original on 12 July 2025.Finally, we have the disubstituted amides of d-lysergic acid: the dimethyl, diethyl. di-isopropyl, and dibutyl amides. They are 3 to 5 times weaker than LSD in their antagonism toward serotonin.
  8. ^abNichols DE (2017). "Chemistry and Structure–Activity Relationships of Psychedelics".Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 1–43.doi:10.1007/7854_2017_475.ISBN 978-3-662-55878-2.PMID 28401524. Retrieved27 July 2025.
  9. ^abcdNichols DE (2001)."LSD and Its Lysergamide Cousins"(PDF).The Heffter Review of Psychedelic Research.2.Heffter Research Institute:80–87.ISSN 1534-9640.Table 3. Affinity for 5-HT2A and 5-HT1A receptors and potency in the rat two-lever drug discrimination assay for selected lysergic acid amides. [...]
  10. ^Stoll A, Hofmann A (1955). "Amide der stereoisomeren Lysergsäuren und Dihydro-lysergsäuren. 38. Mitteilung über Mutterkornalkaloide" [Amides of stereoisomeric lysergic and dihydrolysergic acids. 38. Ergot alkaloids].Helvetica Chimica Acta.38 (2):421–433.Bibcode:1955HChAc..38..421S.doi:10.1002/hlca.19550380207.ISSN 0018-019X.
  11. ^Hofmann A (June 1959)."Psychotomimetic Drugs: Chemical and Pharmacological Aspects"(PDF).Acta Physiologica et Pharmacologica Neerlandica.8:240–258.PMID 13852489.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Ergolines
(incl.lysergines)
Clavines
(6,8-dimethylergolines)
Lysergamides
(lysergic acid amides)
Ergopeptines
(peptide ergolines)
Partial ergolines
Related compounds
Natural sources
Retrieved from "https://en.wikipedia.org/w/index.php?title=DiPLA&oldid=1318136776"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp